148 related articles for article (PubMed ID: 33491479)
1. Economic impact of multigene panel testing for hereditary breast and ovarian cancer.
Byfield SD; Wei H; DuCharme M; Lancaster JM
J Comp Eff Res; 2021 Feb; 10(3):207-217. PubMed ID: 33491479
[No Abstract] [Full Text] [Related]
2. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.
Lumish HS; Steinfeld H; Koval C; Russo D; Levinson E; Wynn J; Duong J; Chung WK
J Genet Couns; 2017 Oct; 26(5):1116-1129. PubMed ID: 28357778
[TBL] [Abstract][Full Text] [Related]
3. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
4. Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome.
Howarth DR; Lum SS; Esquivel P; Garberoglio CA; Senthil M; Solomon NL
Am Surg; 2015 Oct; 81(10):941-4. PubMed ID: 26463285
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.
Adam F; Fluri M; Scherz A; Rabaglio M
BMC Med Genomics; 2023 Jan; 16(1):7. PubMed ID: 36647026
[TBL] [Abstract][Full Text] [Related]
6. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
7. Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario.
Lerner-Ellis J; Mighton C; Lazaro C; Watkins N; Di Gioacchino V; Wong A; Chang MC; Charames GS
J Cancer Res Clin Oncol; 2021 Mar; 147(3):871-879. PubMed ID: 32885271
[TBL] [Abstract][Full Text] [Related]
8. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
10. How to facilitate psychosocial adjustment in women tested for hereditary breast or ovarian cancer susceptibility? Insights from network analysis.
Brédart A; Dick J; Cano A; Robieux L; De Pauw A; Schmutzler R; Stoppa-Lyonnet D; Dolbeault S; Kop JL
Psychooncology; 2020 Mar; 29(3):550-556. PubMed ID: 31823434
[TBL] [Abstract][Full Text] [Related]
11. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
12. Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
Brédart A; Kop JL; Dick J; Cano A; De Pauw A; Anota A; Brunet J; Devilee P; Stoppa-Lyonnet D; Schmutzler R; Dolbeault S
BMJ Open; 2019 Sep; 9(9):e029926. PubMed ID: 31551380
[TBL] [Abstract][Full Text] [Related]
13. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
[TBL] [Abstract][Full Text] [Related]
14. "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
Colas C; Golmard L; de Pauw A; Caputo SM; Stoppa-Lyonnet D
Breast; 2019 Jun; 45():29-35. PubMed ID: 30822622
[TBL] [Abstract][Full Text] [Related]
15. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
16. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.
Frey MK; Kim SH; Bassett RY; Martineau J; Dalton E; Chern JY; Blank SV
Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696
[TBL] [Abstract][Full Text] [Related]
17. Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
Petelin L; James PA; Trainer AH
Intern Med J; 2018 Oct; 48(10):1269-1272. PubMed ID: 30288903
[TBL] [Abstract][Full Text] [Related]
18. Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.
Jones T; Trivedi MS; Jiang X; Silverman T; Underhill M; Chung WK; Kukafka R; Crew KD
J Cancer Educ; 2021 Jun; 36(3):463-469. PubMed ID: 31802423
[TBL] [Abstract][Full Text] [Related]
19. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer as a sentinel for hereditary cancer predisposition.
Young EL; Thompson BA; Neklason DW; Firpo MA; Werner T; Bell R; Berger J; Fraser A; Gammon A; Koptiuch C; Kohlmann WK; Neumayer L; Goldgar DE; Mulvihill SJ; Cannon-Albright LA; Tavtigian SV
BMC Cancer; 2018 Jun; 18(1):697. PubMed ID: 29945567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
